| | √特定对象调研 □分析师会议 | | --- | --- | | 投资者关系 | □媒体采访 □业绩说明会 | | 活动类别 | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他 （请文字说明其他活动内容） | | 参与单位名称及 | 华西证券：晏溶；国泰海通证券：李鹏飞、王宏玉、梁琳；光大理财：丁琨 | | 人员姓名 | | | 时间 | 2026 年 1 月 23 日 | | 地点 | 北京 | | 上市公司接待人 | 田文斌、王依涵 | | 员姓名 | | | 1、 | 公司产品下游需求结构？ | | | 答：目前公司产品主要用于汽车（包括新能源汽车）、消费类电子、工业机器人、 | | | 计算机、节能家电、风力发电机、工业电机等领域。 | | 2、 | 稀土原材料价格波动对公司成本的影响机制？ | | | 答：公司产品价格会参考原材料价格等因素与客户协商确定。 | | 3、 | 公司在人形机器人领域是否有布局?目前最新的进展如何? | | | 答：公司主要产品为钕铁硼永磁材料，已应用于工业机器人领域多年。目前人形 | | 投资者关系活动 | 机器人行业尚未实现规模化量产，待 ...

| 作，率先构筑起技术先发优势。 | | --- | | 2019 年，公司 eCall 终端斩获国内首张欧盟 eCall 认 | | 证证书，同时成为全球首批通过联合国欧洲经济委员会 | | UN-R144 标准认证的企业；2025 年 1 月 6 日，公司再度率先 | | 取得欧盟新一代 NG-eCall 认证，跻身全球首批获此资质的 | | 企业行列。 | | 国内市场方面，公司深度参与行业标准体系构建，作为 | | 国标 AECS 的起草单位之一，工程师团队全程参与标准文本编 | | 制与技术规范制定工作。2025 年 9 月 30 日，公司车载紧急 | | 呼叫系统于中汽研汽车检验中心（天津）顺利通过国标 AECS | | 测试，成为全球首家通过该认证测试的企业。至此，公司车 | | 载终端已实现对全球所有紧急呼叫系统的全面兼容。 | | 公司是国内最早取得欧盟 eCall 认证及英国、阿联酋、 | | 沙特等多个国家和地区测试认证资质的企业，相关产品已实 | | 现大规模量产并远销海外；历经多轮技术迭代与市场验证， | | 公司不仅积累了丰富的项目落地经验，更形成了成熟的周边 | | 技术适配能力 ...

编号：2026-002 | 投资者关系活动 ☑ | 特定对象调研 | □分析师会议 | | --- | --- | --- | | 类别 | □媒体采访 | □业绩说明会 | | | □新闻发布会 | □路演活动 | | | □现场参观 | | | | □其他 （请文字说明其他活动内容） | | | 参与单位名称及 | 东方财富：高博文 | | | 人员姓名 | 德邦证券：曾献强 | | | | 思美传媒：魏靖 | | | | 德邦证券：黄怡然 | | | 时间 2026 | 年 月 日星期五 1 23 | | | 地点 | 公司会议室 | | | 上市公司接待人 | 董事会秘书：黄丽 | | | 员姓名 | 证券事务代表：张晨曦 | | | | 1、投资者高博文先生提问：请介绍一下公司目前主营业务发 | | | | 展情况？ | | | | 董事会秘书黄丽回复：公司主营业务是橡胶高分子材料制品领 | | | 投资者关系活动 | 域，产品主要应用于汽车、电气、航空及核防护四大业务板块。 | | | 主要内容介绍 | 公司汽车业务、电气业务板块在公司整体业务中营收占比较 | | | | 高。这主要得益于公司多年 ...

Group 1: Market Trends and Opportunities - The domestic mini-game market is still in a phase of rapid growth, showcasing significant potential [3] - The strategic value and ceiling of the SLG (Simulation Game) sector continue to break through, with a notable expansion in user base and market value [3] - The long-cycle value of casual games is becoming increasingly evident, driven by fragmented user demands [3] Group 2: Product Development and Strategy - The company has established a leading position in the mini-game market, with multiple mini-games under development, including IP products like "Dou Po Cang Qiong" [3] - The company’s overseas business has maintained stable revenue, with SLG being a core strategic focus, supported by a "lightweight" and "large theme" approach [3] - The company has over 10 self-developed products in its pipeline, focusing on mini-games and SLG development [3] Group 3: AI Integration and Efficiency - The company has achieved over 90% penetration of AI across its operations, significantly enhancing efficiency [4] - AI-driven automatic ad placements exceed 70%, with AI outperforming human operators in various aspects [4] - The company is investing heavily in AI technologies to improve existing business efficiency and secure future strategic advantages [5] Group 4: Talent Development and Organizational Structure - The company is moving towards a younger talent pool, with 80% of its core production team being post-90s generation [4] - The establishment of R&D centers in key talent hubs like Beijing and Shanghai aims to attract top talent and break geographical limitations [4] - The company emphasizes long-term thinking in its product strategies, focusing on longer product lifecycles across various game genres [4] Group 5: Future Goals and Market Positioning - The company aims to return to the top three in the overseas market for Chinese game developers within three years [5] - In the mini-game sector, the goal is to maintain the leading market position while developing headliner products in SLG and casual game categories [5] - The company seeks to achieve industry-leading levels in AI tool capabilities, focusing on unique and refined offerings [5]

证券代码：002317 编号：2026-002 广东众生药业股份有限公司投资者关系活动记录表 | | √ □特定对象调研 □分析师会议 | | --- | --- | | | □媒体采访 □业绩说明会 | | 投资者关系活动 类别 | □新闻发布会 □路演活动 | | | □现场参观 □一对一沟通 | | | □其他（ ） | | 参与单位及人员 | 中信证券股份有限公司、广发证券股份有限公司、宝盈基金管 | | | 理有限公司、上海理成资产管理有限公司分析师、研究员 | | 时间 | 2026 年 1 月 23 日 10:30～11:30 | | 地点 | 众生睿创会议室 | | 形式 | 现场交流 | | 上市公司 | 1、公司副总裁 陈小新 | | 接待人员 | 2、公司董事会秘书 杨威 1、众生睿创与齐鲁制药关于RAY1225注射液的合作情况。 | | | 答：众生睿创与齐鲁制药于 2026 年 1 月 16 日签署《许可 协议》，众生睿创授权齐鲁制药在中国地区（包括中国大陆、 | | | 香港、澳门、台湾，统称"许可地区"）内对 RAY1225 注射液 | | | （以下简称"许可产品"）进行生产与 ...

证券代码：301045 证券简称：天禄科技 苏州天禄光科技股份有限公司 投资者关系活动记录表 编号：2026-008 投资者关系活 动类别 ☑ 特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 ☑ 电话会议 □其他： （请文字说明其他活动内容） 参与单位名称 东吴基金、山西证券、东北证券 时间 2026 年 1 月 23 日 地点 天禄科技公司五楼会议室 公司接待人员 姓名 投资者关系总监：李艳茹女士 投资者关系活 动主要内容介 绍 投资者提出的问题及公司回复情况 1、近期公司公告了变更募集资金的公告，请介绍该公告的 具体情况。 结合公司内外部环境变化以及战略发展需求，为进一步提 高募集资金的使用效率，经审慎决定，公司拟终止原募投项目 "扩建中大尺寸导光板项目"，并将该项目终止后剩余的部分募 集资金投入子公司安徽吉光的TAC膜项目和苏州屹甲的反射式 偏光增亮膜项目。 公司业务以原主业导光板为依托，先通过TAC膜产业布局 向显示行业相邻细分领域的横向延伸，后以此为基础开展反射 式偏光增亮膜项目，以实现公司未来发展的第二增长曲线。两 个光学膜均属于解决"卡脖子"的国产替代 ...

Group 1: R&D Progress - DR10624 has shown strong lipid-lowering effects and safety in Phase II clinical trials, with results presented at the AHA Scientific Sessions 2025. It has been included as a breakthrough therapy for severe hypertriglyceridemia by the CDE in January 2026 [1][2] - HDM1002, an oral GLP-1 receptor agonist, has completed patient enrollment for its Phase III trial in weight management, with top-line data expected in Q3 2026. The study has shown good overall safety without liver enzyme elevation [3] - HDM2005 has reported positive preliminary results in Phase I trials for mantle cell lymphoma and classical Hodgkin lymphoma, and is also undergoing trials for diffuse large B-cell lymphoma and solid tumors [4] Group 2: Upcoming Data Releases - Key data releases expected in 2026 include: - HDM1002 weight management Phase III top-line data - HDM1005 weight management Phase III 40-week data - HDM2005 solid tumor Phase I preliminary data - DR10624 for MASLD/MASH Phase II top-line data [5] Group 3: New Product Approvals and Market Outlook - The company anticipates new drug approvals in 2026, including edaravone tablets and various biosimilars, which are expected to enhance revenue contributions [6][7] - The innovative products, such as Ailaha® and Huijiaojing®, are projected to maintain rapid growth due to their clinical value and market strategies [9] Group 4: Industrial Microbiology and Pet Medicine - The industrial microbiology sector is expected to continue its rapid growth, supported by expanding overseas markets and commercialized products [12] - The HDM7006 project for managing obesity in cats is addressing a significant market gap, with a reported obesity rate of 28.1% among pet cats in China. This product is positioned as a safe and effective GLP-1/GIP dual-target weight management solution [16] Group 5: Strategic Collaborations and Licensing - The company is actively pursuing licensing agreements for its self-developed products and is optimistic about future collaborations [8] - A strategic partnership with MC2 for skincare products aims to leverage innovative technology for daily skin care solutions in the Greater China region [14][15]

Group 1: Company Performance - In 2025, China's heavy truck market total sales reached 1.145 million units, a year-on-year increase of 27% [1] - The company maintained a strong growth trend in production and sales compared to the previous year, with a healthy order backlog [1] - The company continues to hold a leading market share in the heavy truck industry through enhanced product competitiveness and market expansion [1] Group 2: Natural Gas Heavy Trucks - In 2025, cumulative sales of natural gas heavy trucks reached 198,700 units, reflecting a year-on-year growth of 12% [2] - Technological advancements are narrowing the performance gap between natural gas and diesel trucks [2] - The company remains optimistic about the natural gas heavy truck market and plans to enhance product competitiveness and long-term strategic positioning [2] Group 3: New Energy Heavy Trucks - In 2025, cumulative sales of new energy heavy trucks in China reached 231,100 units, a significant year-on-year increase of 182% [3] - In December 2025 alone, sales of new energy heavy trucks totaled 45,300 units, up 189% year-on-year [3] - The new energy heavy truck market is experiencing rapid growth driven by policy support and technological innovation, with the company committed to deepening its involvement in this sector [3] Group 4: Subsidiary Operations - The axle company, a subsidiary, is 51% owned by the company and supplies products to the group's vehicle production units, ensuring stable market demand and revenue [3] - The aftermarket company, a wholly-owned subsidiary, focuses on truck aftermarket services, including parts, oil products, and after-sales services [3] Group 5: Export Performance - The company leverages the international division of the group for its export business, maintaining the industry’s leading position in exports for 21 consecutive years [5] - The export business continues to show good growth, with a market presence in over 150 countries and regions, primarily in Africa, Southeast Asia, Central Asia, and the Middle East [5]

Business Overview - The company has established four core business modules: Engine, Automotive Electronics, Brake Systems, and Hydrogen Energy [2][3]. - In the Engine sector, the company has a leading position with steady growth in cylinder sleeve production and a significant increase in piston sales in 2025 [2]. - The Automotive Electronics segment has seen a rising market share for turbocharger electronic actuators and expansion into air suspension management units [2]. - The Brake Systems focus on bi-metal composite brake drums, leveraging technology and performance advantages to expand product variety [2][3]. - The Hydrogen Energy sector has developed a comprehensive product line including fuel cell engines and compressors, with mass production already underway [3]. Acquisition Strategy - The company plans to acquire 59% of Zhongyuan Jikean, a joint venture established in 2005, to capitalize on the growing AIDC backup power market and shipbuilding industry [3][4]. - Post-acquisition, Zhongyuan Jikean will become a wholly-owned subsidiary, enhancing the company's capabilities in high-end cylinder sleeves and strengthening its competitive edge in the global market [4]. Product Development and Capacity Expansion - The company’s bi-metal brake drums offer superior durability and lightweight design, addressing the automotive industry's shift towards lighter vehicles [5]. - The current annual production capacity for brake drums is 1.6 million units, with plans for further expansion based on market demand [5]. - The Thailand factory has established production lines for cylinder sleeves and is expected to contribute revenue starting in 2026 [6]. Robotics Collaboration - The Shanghai subsidiary is collaborating with Ningbo Puzhi to develop specialized electronic actuators for humanoid robots, leveraging its expertise in automotive electronic systems [6][7]. - This partnership aims to transition from automotive components to a dual focus on automotive and robotics, aligning with industry trends [7]. Shareholder Returns and Risk Management - The company is committed to optimizing profit structures and enhancing shareholder returns through diversified methods, including cash dividends [7]. - There are risks associated with the humanoid robot joint venture, as the product is still in development and has not yet generated revenue [7].

国机精工集团股份有限公司投资者关系活动记录表 编号：2026—004 | | 特定对象调研 □分析师会议 ☑ | | --- | --- | | 投资者关系 | □媒体采访 □业绩说明会 | | 活动类别 | □新闻发布会 □路演活动 | | | □现场参观 □电话会议 | | | □其他 | | 参与单位名称 | 国海证券：张钰莹、孟美辰 | | 及人员姓名 | 南方基金：李金哲 | | 时间 | 2026 年 01 月 23 日 | | 地点 | 国机精工 会议室 | | 上市公司接待 | 董事会秘书：赵祥功 | | 人员姓名 | 投资者关系助理：汪智婷 | | | 一、公司情况介绍 | | | （一）公司概况 | | | 1.基本情况及战略定位 | | | 国机精工的历史，可追溯至 1958 年成立的洛阳轴承研究所和郑 | | | 州磨料磨具磨削研究所，2005 年在深交所上市。公司秉承国机集团"引 | | | 领机械工业发展，推动人类社会进步"的发展理念，践行"精工致远， | | | 利器善事"的企业使命与产业抱负，聚焦精密制造领域，以科技创新 | | | 驱动产业发展，提供满足国家战略需求的关键产品 ...